Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Journal article published in 2017 by
M. H. Pollack,
A. Betof,
H. Dearden,
K. Rapazzo,
I. Valentine,
A. S. Brohl,
K. K. Ancell,
G. V. Long,
A. M. Menzies,
Z. Eroglu,
D. B. Johnson,
A. N. Shoushtari,
Allison Betof Warner 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 